Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. In this ...

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia ...

Overcoming current limitations and expanding the reach of CAR-T therapeutics could unlock promising new treatment ...

The therapy is called autologous transplant ... The other form of blood stem cell transplantation — called “allogeneic,” meaning that the cells come from another person — has long been recognized as a ...

Due to financial, logistical, and regulatory barriers, only two in 10 patients eligible for CAR T-cell therapy in the US ...

Persistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studies. Background: Sipuleucel-T is an investigational autologous active ...

Now a new approach using donor cells brings the hope of giving off-the-shelf CAR T cell immunotherapy to patients in as little as five days. Conventional autologous CAR T therapy requires cells to be ...

The majority of autologous CAR-T cell therapies involve ... Fate Therapeutics is at the forefront of programmed cellular immunotherapy developments designed to treat cancer and immune disorders.

The TILVANCE-301 trial will compare immunotherapy plus adoptive cell ... most promising TCRT at present is the investigational autologous cell therapy IMA203 (NCT03688124), which targets the ...

The presentation will feature the design and objectives of the Phase 1 study, which marks the first clinical application of ...

The autologous immunotherapy consists of the patient’s own T cells engineered to express a chimeric antigen receptor that ...